Evaluation of RGD-Targeted Albumin Carriers for Specific Delivery of Auristatin E to Tumor Blood Vessels
Kai Temming(University of Groningen), Robbert J. Kok(Utrecht University), Eli Dijkers(University Medical Center Groningen), Damon L. Meyer(Seagen (United States)), Roger F. Zabinski(Seagen (United States)), Grietje Molema(University Medical Center Groningen), Klaas Poelstra(University of Groningen)
Cited by 52
Related Papers
Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate
|Clinical Cancer Research|2004|1.2k
Development of potent monoclonal antibody auristatin conjugates for cancer therapy
|Nature Biotechnology|2003|1.2k
cAC10-vcMMAE, an anti-CD30–monomethyl auristatin E conjugate with potent and selective antitumor activity
|Blood|2003|918
Enhanced Activity of Monomethylauristatin F through Monoclonal Antibody Delivery: Effects of Linker Technology on Efficacy and Toxicity
|Bioconjugate Chemistry|2005|511
Contribution of Linker Stability to the Activities of Anticancer Immunoconjugates
|Bioconjugate Chemistry|2008|464